It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The study aimed to determine the associations of Peak Inspiratory Flow (PIF), inhalation technique and adherence with health status and exacerbations in participants with COPD using DPI maintenance therapy. This cross-sectional multi-country observational real-world study included COPD participants aged ≥40 years using a DPI for maintenance therapy. PIF was measured three times with the In-Check DIAL G16: (1) typical PIF at resistance of participant’s inhaler, (2) maximal PIF at resistance of participant’s inhaler, (3) maximal PIF at low resistance. Suboptimal PIF (sPIF) was defined as PIF lower than required for the device. Participants completed questionnaires on health status (Clinical COPD Questionnaire (CCQ)), adherence (Test of Adherence to Inhalers (TAI)) and exacerbations. Inhalation technique was assessed by standardised evaluation of video recordings. Complete data were available from 1434 participants (50.1% female, mean age 69.2 years). GOLD stage was available for 801 participants: GOLD stage I (23.6%), II (54.9%), III (17.4%) and IV (4.1%)). Of all participants, 29% had a sPIF, and 16% were shown able to generate an optimal PIF but failed to do so. sPIF was significantly associated with worse health status (0.226 (95% CI 0.107–0.346), worse units on CCQ; p = 0.001). The errors ‘teeth and lips sealed around mouthpiece’, ‘breathe in’, and ‘breathe out calmly after inhalation’ were related to health status. Adherence was not associated with health status. After correcting for multiple testing, no significant association was found with moderate or severe exacerbations in the last 12 months. To conclude, sPIF is associated with poorer health status. This study demonstrates the importance of PIF assessment in DPI inhalation therapy. Healthcare professionals should consider selecting appropriate inhalers in cases of sPIF.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 General Practitioners Research Institute, Groningen, The Netherlands (GRID:grid.512383.e) (ISNI:0000 0004 9171 3451); University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); Observational and Pragmatic Research Institute, Singapore, Singapore (GRID:grid.500407.6); University of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
2 General Practitioners Research Institute, Groningen, The Netherlands (GRID:grid.512383.e) (ISNI:0000 0004 9171 3451)
3 University of Sydney, Woolcock Institute of Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Sydney Local Health District, Sydney, Australia (GRID:grid.410692.8) (ISNI:0000 0001 2105 7653)
4 University of Minho, Life and Health Sciences Research Institute (ICVS), PT Government Associate Laboratory, School of Medicine, Braga, Portugal (GRID:grid.10328.38) (ISNI:0000 0001 2159 175X)
5 University of Sydney, Woolcock Institute of Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
6 Radboud University Medical Center, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382)
7 Primary Care Respiratory Research Unit, Instituto De Investigación Sanitaria De Baleares (IdISBa), Palma de Mallorca, Spain (GRID:grid.512383.e)
8 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500)
9 Medical University of Silesia, Department of Internal Medicine, Allergology, Clinical Immunology, Katowice, Poland (GRID:grid.411728.9) (ISNI:0000 0001 2198 0923)
10 Careggi University Hospital, Department of Clinical and Experimental Medicine, Florence, Italy (GRID:grid.24704.35) (ISNI:0000 0004 1759 9494)
11 University of Beira Interior, Faculty of Health Sciences, Covilha, Portugal (GRID:grid.7427.6) (ISNI:0000 0001 2220 7094)
12 Observational and Pragmatic Research Institute, Singapore, Singapore (GRID:grid.500407.6); University of Aberdeen, Centre of Academic Primary Care, Division of Applied Health Sciences, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291)
13 Primary Care Respiratory Research Unit, Instituto De Investigación Sanitaria De Baleares (IdISBa), Palma de Mallorca, Spain (GRID:grid.7107.1)
14 University of Crete, Department of Social Medicine, Health Planning Unit, Faculty of Medicine, Rethymno, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437)
15 Imperial College London and Royal Brompton Hospital, Airway Disease, National Heart and Lung Institute (NHLI), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)